Open AccessVilazodone: A landmark antidepressant approval or another “me-too” drug?
Author(s) -
Abimbola Farinde
Publication year - 2013
Publication title -
mental health clinician
Language(s) - English
Resource type - Journals
ISSN - 2168-9709
DOI - 10.9740/mhc.n172355
Subject(s) - antidepressant , major depressive disorder , pharmacodynamics , medicine , drug , pharmacokinetics , psychiatry , pharmacology , psychology , anxiety , cognition
Vilazodone is a novel antidepressant which is indicated for the treatment of major depressive disorder (MDD) in adult patients. This article reviews the pharmacodynamics and pharmacokinetics of vilazodone, and discusses published and ongoing research on the medication.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom